Shopping Cart
- Remove All
- Your shopping cart is currently empty
740 Y-P (740YPDGFR) is a PI3K activator with cell permeability. 740 Y-P binds GST fusion proteins containing the N-and C-terminal SH2 domains of p85.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $89 | In Stock | |
2 mg | $139 | In Stock | |
5 mg | $265 | In Stock | |
10 mg | $393 | In Stock | |
25 mg | $658 | In Stock | |
50 mg | $937 | In Stock |
Description | 740 Y-P (740YPDGFR) is a PI3K activator with cell permeability. 740 Y-P binds GST fusion proteins containing the N-and C-terminal SH2 domains of p85. |
Targets&IC50 | SGC - 996 Cell:9.32 μM, NOZ cells:9.91 μM |
In vitro | METHODS: C2 muscle cells were treated with 740 Y-P (50 μg/mL) for 48 hours, and the cell cycle was observed and analyzed using an ultraviolet fluorescence microscope. RESULTS: Mitosis in the 740 Y-P-specific stimulation medium was superior to EGF or FGF in stimulating the entry into the S phase. It showed that the percentage of S phase cells in C2 cells was 48.3%. [1] METHODS: PC12 cells were treated with 740 YP (30 μM) for 24 hours, and the LC3-II/LC3-I levels were detected by western blot. RESULTS: 740 YP significantly inhibited the LC3-II/LC3-I levels in PC12 cells induced by GO. [2] |
In vivo | METHODS: To study the neuroprotective effect of 740 Y-P, 740 Y-P (10 mg/kg) was intraperitoneally injected into the rat model of Alzheimer's disease (AD) for 6 weeks. RESULTS: 740 Y-P can reduce the ROS (reactive oxygen species) level in hippocampal tissue after treatment with Aβ(25-32), and increase the phosphorylation degree of AKT and PI3K. This indicates that 740 Y-P has a certain neuroprotective effect in vivo, which may be achieved by activating the PI3K/Akt signaling pathway. [3] METHODS: To study the role of 740 Y-P in cardiac hypertrophy, 740 Y-P (10 mg/kg) was intraperitoneally injected into mice for 6 weeks. RESULTS: 740 Y-P can significantly increase the ratio of heart weight to body weight (HW/BW) and the ratio of heart weight to tibial length (HW/TL), and increase the cross-sectional area of cardiomyocytes. Furthermore, 740 Y-P can also increase the expression of hypertrophy related genes such as ANP, BNP and β-MHC in cardiomyocytes, indicating that it can promote cardiac hypertrophy in vivo. [4] METHODS: To study the analgesic effect of 740 Y-P, 740 Y-P (1, 5, 10, 20 µg/5 µL) was intrathecally injected into a mouse model of chronic constriction injury of the sciatic nerve (CCI). RESULTS: At doses of 10 and 20 µg/5 µL, 740 Y-P can significantly alleviate tactile and thermal hypersensitivity caused by CCI. 740 Y-P showed significant analgesic effects within 1.5, 3 and 5 hours after injection, but the effect was no longer significant after 24 hours. [5] |
Synonyms | PDGFR 740Y-P, 740YPDGFR |
Molecular Weight | 3270.7 |
Formula | C141H222N43O39PS3 |
Cas No. | 1236188-16-1 |
Smiles | C([C@@H](C(N[C@@H](CC1=CC=CC=C1)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CC=2C=3C(NC2)=CC=CC3)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(NCC(N[C@@H](CC4=CC=C(OP(=O)(O)O)C=C4)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(O)=O)CO)=O)CCSC)=O)CC(O)=O)=O)CCSC)=O)=O)=O)=O)CC(O)=O)=O)CO)=O)CCCCN)=O)CCCCN)=O)=O)CCCCN)=O)CCSC)=O)CCCNC(=N)N)=O)CCCNC(=N)N)=O)CC(N)=O)=O)CCC(N)=O)=O)=O)NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](CCCNC(=N)N)N)=O)CCC(N)=O)=O)[C@H](CC)C)=O)CCCCN)=O)[C@H](CC)C)=O)C=5C=6C(NC5)=CC=CC6 |
Relative Density. | 1.51 g/cm3 (Predicted) |
Sequence | Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-Ser-Asp-Gly-Gly-{Tyr(PO2)}-Met-Asp-Met-Ser |
Sequence Short | RQIKIWFQNRRMKWKKSDGG-{Tyr(PO2)}-MDMS |
Storage | store at low temperature,store under nitrogen,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||
Solubility Information | DMSO: 50 mg/mL (15.29 mM), Sonication is recommended. ![]() H2O: 5.5 mg/mL (1.68 mM), when pH is adjusted with HCl. Sonication is recommmended. ![]() | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
H2O/DMSO
DMSO
|
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.